NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Price, Quote, News and Overview
NASDAQ:NAUT - Nasdaq - US63909J1088 - Common Stock - Currency: USD
NAUT Quote, Performance and Key Statistics
NASDAQ:NAUT (8/5/2025, 12:16:38 PM)
0.75
+0.01 (+1.21%)
The current stock price of NAUT is 0.75 USD. In the past month the price decreased by -6.91%. In the past year, price decreased by -67.36%.
NAUT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.44 | 177.18B | ||
| DHR | DANAHER CORP | 26.63 | 143.56B | ||
| A | AGILENT TECHNOLOGIES INC | 21.35 | 32.75B | ||
| IQV | IQVIA HOLDINGS INC | 16 | 31.19B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.13 | 25.61B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 34.51 | 17.27B | ||
| WAT | WATERS CORP | 23.16 | 16.86B | ||
| ILMN | ILLUMINA INC | 23.87 | 15.72B | ||
| ICLR | ICON PLC | 12.63 | 13.00B | ||
| MEDP | MEDPACE HOLDINGS INC | 32.51 | 12.28B | ||
| QGEN | QIAGEN N.V. | 21.79 | 10.85B | ||
| RVTY | REVVITY INC | 18.31 | 10.55B |
Related stock screener links
About NAUT
Company Profile
Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. The company is headquartered in Seattle, Washington and currently employs 155 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Company Info
NAUTILUS BIOTECHNOLOGY INC
2701 Eastlake Ave East
Seattle WASHINGTON US
CEO: Adam Stone
Employees: 164
Phone: 12063332001
NAUTILUS BIOTECHNOLOGY INC / NAUT FAQ
What is the stock price of NAUTILUS BIOTECHNOLOGY INC today?
The current stock price of NAUT is 0.75 USD. The price increased by 1.21% in the last trading session.
What is the ticker symbol for NAUTILUS BIOTECHNOLOGY INC stock?
The exchange symbol of NAUTILUS BIOTECHNOLOGY INC is NAUT and it is listed on the Nasdaq exchange.
On which exchange is NAUT stock listed?
NAUT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NAUTILUS BIOTECHNOLOGY INC stock?
8 analysts have analysed NAUT and the average price target is 1.79 USD. This implies a price increase of 138% is expected in the next year compared to the current price of 0.75. Check the NAUTILUS BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NAUTILUS BIOTECHNOLOGY INC worth?
NAUTILUS BIOTECHNOLOGY INC (NAUT) has a market capitalization of 94.61M USD. This makes NAUT a Micro Cap stock.
How many employees does NAUTILUS BIOTECHNOLOGY INC have?
NAUTILUS BIOTECHNOLOGY INC (NAUT) currently has 164 employees.
What are the support and resistance levels for NAUTILUS BIOTECHNOLOGY INC (NAUT) stock?
NAUTILUS BIOTECHNOLOGY INC (NAUT) has a support level at 0.71 and a resistance level at 0.75. Check the full technical report for a detailed analysis of NAUT support and resistance levels.
Should I buy NAUTILUS BIOTECHNOLOGY INC (NAUT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NAUT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NAUT, evaluating the profitability, health, valuation and growth aspects
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Sales and EPS estimates to see what analysts future expectations are.
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Insider and Institutional Ownership to learn about the owners and their transactions.
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Chart to make your own analysis
- NAUTILUS BIOTECHNOLOGY INC (NAUT) Latest news and press-releases to stay up to date.
Does NAUTILUS BIOTECHNOLOGY INC (NAUT) stock pay dividends?
NAUT does not pay a dividend.
When does NAUTILUS BIOTECHNOLOGY INC (NAUT) report earnings?
NAUTILUS BIOTECHNOLOGY INC (NAUT) will report earnings on 2025-10-27, before the market open.
What is the Price/Earnings (PE) ratio of NAUTILUS BIOTECHNOLOGY INC (NAUT)?
NAUTILUS BIOTECHNOLOGY INC (NAUT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
What is the Short Interest ratio of NAUTILUS BIOTECHNOLOGY INC (NAUT) stock?
The outstanding short interest for NAUTILUS BIOTECHNOLOGY INC (NAUT) is 0.34% of its float. Check the ownership tab for more information on the NAUT short interest.
NAUT Technical Analysis
NAUT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NAUT. While NAUT has a great health rating, there are worries on its profitability.
NAUT Financial Highlights
Over the last trailing twelve months NAUT reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 7.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.16% | ||
| ROE | -35.31% | ||
| Debt/Equity | 0 |
NAUT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NAUT. The Buy consensus is the average rating of analysts ratings from 8 analysts.